Abstract
As we enter the 2000's it is clear that cytokine blockade is an effective therapeutic strategy for rheumatoid arthritis. In this brief review, we will review the rationale for anti TNFalpha therapy, the current status of therapy and focus on the regulation of TNFalpha production in rheumatoid synovium. New approaches to studying TNF regulation in RA and of elucidating the controversial role of T cells in this complex disease will be described.
MeSH terms
-
Adenoviridae / immunology
-
Arthritis, Rheumatoid / immunology
-
Arthritis, Rheumatoid / therapy*
-
Cytokines / antagonists & inhibitors*
-
DNA-Binding Proteins / pharmacology
-
Humans
-
I-kappa B Proteins*
-
Interleukin-1 / biosynthesis
-
NF-KappaB Inhibitor alpha
-
NF-kappa B / antagonists & inhibitors
-
T-Lymphocytes / immunology
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / biosynthesis
Substances
-
Cytokines
-
DNA-Binding Proteins
-
I-kappa B Proteins
-
Interleukin-1
-
NF-kappa B
-
NFKBIA protein, human
-
Tumor Necrosis Factor-alpha
-
NF-KappaB Inhibitor alpha